Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quercetin and Curcumin for Mild COVID-19
NCT05130671Completed
- Sponsor
- King Edward Medical University
- Start
- Oct 2021
- Primary completion
- Dec 2021
- Modality
- Nucleic Acid-Directed Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of quercetin and curcumin in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by King Edward Medical University. Primary endpoints: Testing negative for SARS-CoV-2 by Reverse Transcription Polymerase Chain Reaction (RT-PCR) at Day 7 and COVID-19 symptoms improvement at Day 7. Started Oct 2021; status: completed.
02
Drugs
quercetincurcumin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05130671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05130671.